X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-03-16 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | SVP, COMM, MEDICAL AFFAIRS | S - Sale | $13.96 | -31,067 | 232,699 | -12% | -$433,637 | ||||||
2026-03-17 | CYTK | Cytokinetics Inc | Lee Sung | EVP, CFO | S - Sale | $62.15 | -4,935 | 87,127 | -5% | -$306,710 | ||||||
2026-03-17 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $62.15 | -8,542 | 71,573 | -11% | -$530,885 | ||||||
2026-03-17 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale | $62.15 | -12,033 | 153,902 | -7% | -$747,851 | ||||||
2026-03-17 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $62.15 | -36,601 | 434,496 | -8% | -$2,274,752 | ||||||
2026-03-16 | CRNX | Crinetics Pharmaceuticals, Inc. | Knight Jeff E. | COO | S - Sale | $37.37 | -9,911 | 112,018 | -8% | -$370,411 | ||||||
2026-03-16 | CRNX | Crinetics Pharmaceuticals, Inc. | Betz Stephen F. | Chief Scientific Officer | S - Sale | $37.37 | -10,612 | 137,101 | -7% | -$396,610 | ||||||
2026-03-16 | CRNX | Crinetics Pharmaceuticals, Inc. | Struthers Richard Scott | Pres, CEO | S - Sale | $37.37 | -21,981 | 1,382,983 | -2% | -$821,513 | ||||||
2026-03-18 | TNXP | Tonix Pharmaceuticals Holding Corp. | Lederman Seth | CEO | P - Purchase | $14.89 | +15,000 | 19,007 | +374% | +$223,350 | ||||||
2026-03-18 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $62.07 | -1,930 | 78,185 | -2% | -$119,795 | ||||||
| D | 2026-03-16 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale+OE | $5.84 | -41,666 | 1,841,812 | -2% | -$243,329 | |||||
| D | 2026-03-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $536.75 | -9,500 | 679,872 | -1% | -$5,099,104 | |||||
2026-03-16 | LFVN | Lifevantage Corp | Lewis Darwin | Dir | P - Purchase | $5.23 | +1,055 | 136,563 | +1% | +$5,518 | ||||||
2026-03-17 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | GC | S - Sale | $2.70 | -5,708 | 679,348 | -1% | -$15,429 | ||||||
2026-03-17 | ESPR | Esperion Therapeutics, Inc. | Koenig Sheldon L. | Pres, CEO | S - Sale | $2.72 | -25,578 | 2,172,699 | -1% | -$69,547 | ||||||
2026-03-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | CFO | S - Sale | $2.71 | -6,424 | 713,602 | -1% | -$17,377 | ||||||
2026-03-16 | IRD | Opus Genetics, Inc. | Schachle Joseph K | COO | S - Sale | $5.25 | -3,719 | 300,781 | -1% | -$19,525 | ||||||
2026-03-16 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | S - Sale | $5.25 | -2,816 | 190,312 | -1% | -$14,770 | ||||||
2026-03-16 | IRD | Opus Genetics, Inc. | Magrath George | CEO | S - Sale | $5.21 | -24,438 | 1,750,855 | -1% | -$127,327 | ||||||
2026-03-16 | IRD | Opus Genetics, Inc. | Jayagopal Ashwath | Chief Scientific, Dev. Ofc. | S - Sale | $5.12 | -3,719 | 516,775 | -1% | -$19,046 | ||||||
| D | 2026-03-16 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $16.15 | -25,492 | 3,622 | -88% | -$411,607 | |||||
| D | 2026-03-16 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale+OE | $28.09 | -10,000 | 105,211 | -9% | -$280,861 | |||||
2026-03-17 | IRWD | Ironwood Pharmaceuticals Inc | Denner Alexander J | Dir | S - Sale | $3.05 | -6,730,800 | 9,444,944 | -42% | -$20,530,448 | ||||||
| D | 2026-03-16 | CYRX | Cryoport, Inc. | Zecchini Edward J | See Remarks | S - Sale+OE | $8.00 | -2,014 | 109,719 | -2% | -$16,112 | |||||
| D | 2026-03-16 | CYRX | Cryoport, Inc. | Shelton Jerrell | Pres, CEO | S - Sale+OE | $8.00 | -7,918 | 1,054,501 | -1% | -$63,344 | |||||
| D | 2026-03-16 | CYRX | Cryoport, Inc. | Sawicki Mark W | Chief Scientific Officer | S - Sale+OE | $8.00 | -3,235 | 103,697 | -3% | -$25,880 | |||||
| D | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale+OE | $91.98 | -7,287 | 49,788 | -13% | -$670,243 | |||||
| D | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | Quan Joanne | CHIEF MEDICAL OFFICER | S - Sale+OE | $91.98 | -7,287 | 18,864 | -28% | -$670,243 | |||||
| D | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $90.76 | -2,000 | 0 | -100% | -$181,520 | |||||
| D | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Pres, COO | S - Sale+OE | $91.98 | -16,515 | 40,272 | -29% | -$1,519,015 | |||||
| D | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $91.98 | -4,732 | 8,429 | -36% | -$435,239 | |||||
| D | 2026-03-16 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $91.98 | -40,985 | 381,809 | -10% | -$3,769,714 | |||||
| D | 2026-03-16 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | CEO | S - Sale+OE | $46.71 | -14,583 | 297,295 | -5% | -$681,108 | |||||
2026-03-13 | NGNE | Neurogene Inc. | Cobb Stuart | Chief Scientific Officer | S - Sale | $20.81 | -6,797 | 30,497 | -18% | -$141,446 | ||||||
2026-03-13 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Pres, CFO | S - Sale | $20.81 | -4,045 | 105,798 | -4% | -$84,176 | ||||||
2026-02-17 | DRMA | Dermata Therapeutics, Inc. | Bedoya-Toro Munera Maria E | SVP, Regulatory Affairs | P - Purchase | $1.27 | +1,000 | 1,046 | >999% | +$1,270 | ||||||
| D | 2026-03-16 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $19.66 | -12,500 | 200,641 | -6% | -$245,714 | |||||
2026-03-13 | STOK | Stoke Therapeutics, Inc. | Levin Arthur A | Dir | S - Sale | $36.80 | -605 | 22,216 | -3% | -$22,264 | ||||||
2026-03-13 | NATR | Natures Sunshine Products Inc | Yates Bryant J | EVP, Pres, Europe | S - Sale | $24.35 | -19,516 | 85,154 | -19% | -$475,215 | ||||||
| D | 2026-03-16 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $533.90 | -9,500 | 679,872 | -1% | -$5,072,019 | |||||
2026-03-13 | NATR | Natures Sunshine Products Inc | Norman Daniel C | EVP, Pres, Asia | S - Sale | $24.52 | -15,383 | 52,083 | -23% | -$377,191 | ||||||
2026-03-16 | UPB | Upstream Bio, Inc. | Gray Michael | CFO, COO | S - Sale | $9.29 | -852 | 29,648 | -3% | -$7,915 | ||||||
2026-03-16 | UPB | Upstream Bio, Inc. | Deykin Aaron | Chief Medical Officer | S - Sale | $9.29 | -894 | 32,687 | -3% | -$8,305 | ||||||
2026-03-16 | UPB | Upstream Bio, Inc. | Sutherland Everett Rand | CEO | S - Sale | $9.29 | -2,093 | 72,907 | -3% | -$19,444 | ||||||
2026-03-16 | UPB | Upstream Bio, Inc. | Ambrose Allison | GC | S - Sale | $9.29 | -475 | 16,525 | -3% | -$4,413 | ||||||
2026-03-16 | UPB | Upstream Bio, Inc. | Houghton Adam | Chief Business Officer | S - Sale | $9.29 | -699 | 24,301 | -3% | -$6,494 | ||||||
2026-03-17 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale | $533.51 | -45 | 125 | -26% | -$24,008 | ||||||
| D | 2026-03-17 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $25.65 | -417 | 76,140 | -1% | -$10,696 | |||||
2026-03-13 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale | $36.30 | -35,365 | 174,473 | -17% | -$1,283,834 | ||||||
2026-03-13 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale | $38.00 | -16,261 | 148,397 | -10% | -$617,918 | ||||||
| D | 2026-03-13 | LQDA | Liquidia Corp | Singh Raman | Dir | S - Sale+OE | $36.04 | -20,000 | 38,755 | -34% | -$720,828 | |||||
2026-03-16 | ORKA | Oruka Therapeutics, Inc. | Klein Lawrence Otto | CEO | S - Sale | $41.30 | -1,729 | 927,309 | 0% | -$71,408 | ||||||
2026-03-16 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale | $41.30 | -395 | 18,863 | -2% | -$16,314 | ||||||
2026-03-16 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | COO | S - Sale | $41.30 | -600 | 236,984 | 0% | -$24,780 | ||||||
| D | 2026-03-16 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $40.91 | -7,641 | 33,377 | -19% | -$312,560 | |||||
2026-03-16 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | GC | S - Sale | $41.30 | -733 | 31,767 | -2% | -$30,273 | ||||||
2026-03-13 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $481.79 | -2,329 | 35,405 | -6% | -$1,122,089 | ||||||
| DM | 2026-03-12 | CYRX | Cryoport, Inc. | Stefanovich Robert | CFO | S - Sale+OE | $7.78 | -41,443 | 280,371 | -13% | -$322,330 | |||||
| D | 2026-03-13 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale+OE | $2.50 | -120,312 | 62,586 | -66% | -$300,816 | |||||
| AD | 2026-03-13 | CNTA | Centessa Pharmaceuticals Plc | Anderson Karen M. | Chief People Officer | S - Sale+OE | $26.25 | -120,029 | 62,085 | -66% | -$3,150,673 | |||||
| M | 2026-03-12 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $68.76 | -80,000 | 5,308,584 | -1% | -$5,501,068 | |||||
| DM | 2026-03-12 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $26.61 | -20,406 | 76,140 | -21% | -$542,973 | |||||
2026-03-16 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $61.03 | -1,709 | 46,149 | -4% | -$104,300 | ||||||
2026-03-16 | UTHR | United Therapeutics Corp | Olian Judy D. | Dir | S - Sale | $535.44 | -200 | 4,445 | -4% | -$107,088 | ||||||
| DM | 2026-03-12 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $98.08 | -35,104 | 65,604 | -35% | -$3,442,856 | |||||
| D | 2026-03-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $538.00 | -9,500 | 639,489 | -1% | -$5,110,967 | |||||
2026-03-16 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $4.76 | -785 | 567,775 | 0% | -$3,737 | ||||||
| D | 2026-03-13 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $48.91 | -5,280 | 113,040 | -4% | -$258,245 | |||||
| D | 2026-03-13 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | S - Sale+OE | $18.63 | -1,966 | 91,026 | -2% | -$36,623 | |||||
| D | 2026-03-13 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale+OE | $18.63 | -1,281 | 6,494 | -16% | -$23,862 | |||||
| D | 2026-03-13 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $18.63 | -1,703 | 19,999 | -8% | -$31,723 | |||||
2026-03-13 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale | $50.38 | -35,000 | 2,199,244 | -2% | -$1,763,124 | ||||||
| D | 2026-03-13 | ZLAB | Zai Lab Ltd | Amado Rafael | See Remarks | S - Sale+OE | $18.63 | -2,957 | 44,757 | -6% | -$55,083 | |||||
2026-03-12 | SUPN | Supernus Pharmaceuticals, Inc. | Hudson Frederick M. | Dir | S - Sale | $50.61 | -5,369 | 60,413 | -8% | -$271,725 | ||||||
2026-03-13 | NATR | Natures Sunshine Products Inc | Lanoy Jonathan David | SVP, Chief Accounting Officer | S - Sale | $24.70 | -4,000 | 46,405 | -8% | -$98,800 | ||||||
| DM | 2026-03-12 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $537.81 | -9,500 | 639,489 | -1% | -$5,109,148 | |||||
2026-03-13 | MBX | Mbx Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO | P - Purchase | $28.41 | +18,500 | 1,215,051 | +2% | +$525,663 | ||||||
| D | 2026-03-12 | DNTH | Dianthus Therapeutics, Inc. /De/ | Garcia Marino | CEO, Pres | S - Sale+OE | $81.49 | -122,918 | 0 | -100% | -$10,016,381 | |||||
| D | 2026-03-12 | DNTH | Dianthus Therapeutics, Inc. /De/ | Carr Edward | CHIEF ACCOUNTING OFFICER | S - Sale+OE | $81.49 | -43,682 | 0 | -100% | -$3,559,495 | |||||
| D | 2026-03-12 | DNTH | Dianthus Therapeutics, Inc. /De/ | Randhawa Simrat | EVP, Head of R, D | S - Sale+OE | $81.48 | -33,830 | 0 | -100% | -$2,756,468 | |||||
| D | 2026-03-13 | XENE | Xenon Pharmaceuticals Inc. | Kenney Christopher John | Chief Medical Officer | S - Sale+OE | $55.23 | -1,410 | 7,069 | -17% | -$77,867 | |||||
| D | 2026-03-13 | XENE | Xenon Pharmaceuticals Inc. | Difabio Andrea | GC | S - Sale+OE | $55.23 | -1,342 | 7,301 | -16% | -$74,112 | |||||
| D | 2026-03-13 | XENE | Xenon Pharmaceuticals Inc. | Mortimer Ian | Pres, CEO | S - Sale+OE | $55.23 | -7,308 | 34,223 | -18% | -$403,584 | |||||
2026-03-12 | SRPT | Sarepta Therapeutics, Inc. | Mayo Stephen | Dir | S - Sale | $17.02 | -7,239 | 1,765 | -80% | -$123,208 | ||||||
| D | 2026-03-11 | LGND | Ligand Pharmaceuticals Inc | Espinoza Octavio | CFO | S - Sale+OE | $225.00 | -3,057 | 21,010 | -13% | -$687,825 | |||||
| D | 2026-03-13 | CNTA | Centessa Pharmaceuticals Plc | Anderson Karen M. | Chief People Officer | S - Sale+OE | $26.25 | -120,029 | 62,085 | -66% | -$3,150,673 | |||||
2026-03-13 | CNTA | Centessa Pharmaceuticals Plc | Weinhoff Gregory M | Chief Business Officer | S - Sale | $26.33 | -73,196 | 65,925 | -53% | -$1,927,131 | ||||||
2026-03-12 | CRNX | Crinetics Pharmaceuticals, Inc. | Vivaldi Coelho Rogerio | Dir | S - Sale | $36.15 | -5,000 | 16,300 | -23% | -$180,761 | ||||||
2026-03-11 | ANIP | Ani Pharmaceuticals Inc | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | S - Sale | $74.91 | -4,772 | 38,730 | -11% | -$357,471 | ||||||
2026-03-13 | ANIP | Ani Pharmaceuticals Inc | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $71.64 | -3,162 | 91,309 | -3% | -$226,526 | ||||||
2026-03-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $72.62 | -500 | 79,390 | -1% | -$36,310 | ||||||
| D | 2026-03-11 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $300.00 | -341 | 318,370 | 0% | -$102,300 | |||||
2026-03-12 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $64.08 | -2,662 | 396,920 | -1% | -$170,581 | ||||||
2026-03-11 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $19.35 | +2,000 | 13,500 | +17% | +$38,700 | ||||||
2026-03-11 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Dir | S - Sale | $19.52 | -129,672 | 4,644,386 | -3% | -$2,530,562 | ||||||
2026-03-13 | INDV | Indivior Pharmaceuticals, Inc. | Ryan Barbara | Dir | P - Purchase | $31.09 | +8 | 5,724 | 0% | +$249 | ||||||
2026-03-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | McKechnie Duncan | EVP, Chief Commercial Officer | S - Sale | $498.42 | -2,633 | 12,489 | -17% | -$1,312,340 | ||||||
2026-03-11 | ONCY | Oncolytics Biotech Inc | Parsons James T. | Dir | P - Purchase | $1.03 | +10,000 | 41,849 | +31% | +$10,300 | ||||||
2026-03-12 | ONCY | Oncolytics Biotech Inc | Kelly Jared | CEO | P - Purchase | $0.96 | +5,050 | 114,050 | +5% | +$4,848 | ||||||
| D | 2026-03-10 | KRRO | Korro Bio, Inc. | Yang Rick | 10% | P - Purchase | $11.11 | +207,100 | 1,297,893 | +19% | +$2,300,881 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |